Evidence map›Paper›PMID 38356007›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2024

Validity and responsiveness of EQ-5D-Y in children with haematological malignancies and their caregivers.

Wenjing Zhou, Anle Shen, Zhihao Yang, Pei Wang, Bin Wu, Michael Herdman, Jan Busschbach, Nan Luo

Open access · greenAbstract readValidation Study
PubMed Publisher
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Wenjing Zhou *Department of Paediatrics, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.ORCID http://orcid.org/0000-0003-0770-4564
Anle Shen *Department of Pharmacy, Shanghai Children's Medical Centre, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Zhihao YangHealth Services Management Department, Guizhou Medical University, Guiyang, China.
Pei WangSchool of Public Health, Fudan University, Shanghai, China.
Bin WuClinical Research Unit, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Michael HerdmanSaw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
Jan BusschbachDepartment of Psychiatry, Section Medical Psychology and Psychotherapy, Erasmus Medical Centre, Rotterdam, The Netherlands.
Nan LuoSaw Swee Hock School of Public Health, National University of Singapore, 12 Science Drive 2, Singapore, Singapore. ephln@nus.edu.sg.ORCID http://orcid.org/0000-0001-7980-6979
National University of Singapore · SGRenji Hospital · CNErasmus University Rotterdam · NLFudan University · CNGuiyang Medical University · CNShanghai Children's Medical Center · CN

Funding

EuroQol Research Foundation 20170330National Natural Science Foundation of China 7172810
6 · The paper itself

Abstract

The psychometric properties of the EQ-5D-Y have not been widely tested in severely ill children. The aim of this study was to assess and compare the validity and responsiveness of the EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric inpatients with haematological malignancies and caregivers. Respondents completed the interviewer-administered self-complete or proxy version of the EQ-5D-Y-3L and EQ-5D-Y-5L and an overall health assessment twice on different days. Known-groups validity was assessed by comparing patients who differed in overall health and Eastern Cooperative Oncology Group (ECOG) performance. Responsiveness to worsened health was assessed using standardised effect size (SES) for patients with worsened ECOG grade, self-reported rating, or chemotherapy initiation. Ninety-six dyads completed the baseline questionnaires. A smaller proportion of patients reported "no problems" on the EQ-5D-Y-5L compared to EQ-5D-Y-3L for most of the five dimensions. Patients in poor health reported more problems in all dimensions and had higher EQ-5D-Y-5L level sum score, lower EQ VAS and EQ-5D-Y-3L index scores (Cohen's d ES: 0.32-1.38 for patients; 0.50-2.05 for caregivers). There was a mild to good responsiveness to worsened health condition based on ECOG (SES: 0.14-0.61 for patients; 0.40-0.96 for caregivers), suggesting the proxy version was slightly responsive than the self-complete version of both instruments. The results demonstrated validity and responsiveness for both the self-complete and proxy versions of the EQ-5D-Y-3L and EQ-5D-Y-5L. The proxy and 5-level versions of the instrument were more sensitive than the self-complete and 3-level versions in this patient group.

Indexed as

CaregiversHematologic NeoplasmsPsychometricsQuality of LifeAdolescentChildChild, PreschoolFemaleHealth StatusHumansMaleReproducibility of ResultsSurveys and QuestionnairesEQ-5D-Y-3LEQ-5D-Y-5LHaematological malignanciesProxyResponsivenessValidity

Identifiers

PMID38356007
OpenAlexW4391824173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.